Hepatitis B and hepatitis C need different checks before musculoskeletal platelet-rich plasma. A history of hepatitis does not automatically mean treatment is impossible, but a clinic should not decide from the name of the infection alone. Current viral status, treatment history, liver health and the reason for the injection all matter.
Do not stop antiviral treatment or change specialist follow-up to prepare for an elective injection. The clinician considering PRP may need advice from the team managing your hepatitis before a decision can be made.
What does current PRP guidance say?
The 2025 GRIIP formal consensus says PRP may be performed in people with hepatitis B if the viral load is undetectable. For hepatitis C, it says injection should be performed only after antiviral treatment has been completed. These are separate recommendations, not a single generic rule for all hepatitis. [1]
The hepatitis B recommendation is graded D and the hepatitis C recommendation is graded D. They support a cautious clinical decision but do not establish safety in every circumstance or prove that PRP will help a particular joint or tendon problem. [1]
Ask The Wellness about a suitability assessment and provide your diagnosis, current treatment and recent specialist information before arranging treatment. No online article can substitute for reviewing the actual record.
Why does an antibody result not answer the whole question?
A past positive screening result, a diagnosis recorded years ago and a current viral-load result are different pieces of information. The clinician needs to understand which infection was identified, what treatment was given and what the current specialist assessment says.
Do not try to interpret a series of hepatitis markers from a single screenshot or assume that feeling well establishes viral control. Ask your treating team which result describes the current status and whether further testing or review is needed for the proposed procedure.
What is different about hepatitis B?
The PRP-specific consensus links consideration of treatment to an undetectable viral load. That is a condition to verify from the clinical record, not something to infer from taking tablets or having no symptoms. The recommendation still needs to be read alongside your other medical conditions, medicines and the injection indication. [1]
The consensus does not specify a universal shelf life for a viral-load result that would clear every future injection. The reviewing clinicians should decide whether the available result is sufficiently current in your circumstances. There is no reason to invent a standard interval for everyone.
What is different about hepatitis C?
The consensus says musculoskeletal PRP should be performed only after antiviral treatment has been completed. Completion is a treatment-history fact that needs confirmation. It should not be confused with a general assumption that a person has recovered because symptoms have improved. [1]
The article's recommendation is not a complete hepatitis C follow-up protocol. Your treating team should explain the meaning of post-treatment results and whether any further liver or infection-related review is needed. Do not replace that plan with a clinic's generic injection checklist.
Does controlled hepatitis guarantee that PRP is suitable?
No. Viral status is one part of assessment. The clinician still needs to consider the condition being treated, liver-related complications, blood-count abnormalities, medicines and other relevant health issues. If important information is missing, delaying an elective procedure is reasonable.
The consensus recommends investigating a significant blood-count abnormality before PRP. It also calls for an individual benefit-risk assessment and informed consent that reflects comorbidities. A reassuring viral result should not be used to skip the rest of that process. [1]
Why does using your own blood not remove every concern?
PRP is autologous, meaning it is prepared from your blood. That does not make it automatically free of risk. The 2025 consensus discusses the possibility that PRP can carry pathogens and the importance of assessing infectious conditions before injection. [1]
Standard precautions and careful preparation remain necessary. You should be able to discuss your history confidentially and without stigma. Good clinical care means assessing relevant facts, not excluding someone because a diagnostic label is uncomfortable to discuss.
Does this guidance also apply to hair or facial PRP?
Not automatically. The consensus was developed for musculoskeletal disease. Its authors explicitly limit its scope because they did not involve specialists covering other PRP indications. Applying the recommendation to hair or cosmetic treatment would go beyond what this source establishes. [1]
If you are considering a different use of PRP, ask for evidence and a suitability assessment specific to that indication. A clinic should be clear about where it has direct evidence and where it is making a cautious extrapolation.
What about the chance that PRP will help?
A statement about whether an injection may be considered is not evidence that it works well for every condition. The diagnosis, preparation and treatment comparison matter. Complex medical histories can also be underrepresented in trials.
Ask the clinician why PRP is being proposed, what alternatives exist and what improvement would count as worthwhile. Ask how the outcome will be measured and what happens if it does not help. The consensus supports considering alternatives and giving personalised information before consent. [1]
How to prepare for a review
Bring the hepatitis diagnosis, treatment dates, current medicines and recent specialist letters or relevant laboratory results. Include liver and blood-count results if available, previous injection reactions and imaging of the affected joint or tendon. You do not need to send more private information than the reviewing team requires through an agreed secure route.
Ask which missing result or clinical opinion would change the decision. If the clinic needs specialist advice, clarify who will request it and whether the procedure is being held until that question is answered.
Contact The Wellness to discuss assessment before committing to a treatment course. The right outcome is a clear, individual plan, which may include proceeding, deferring or choosing another treatment.
Source and limits
[1] Eymard and colleagues: 2025 GRIIP formal consensus on PRP and comorbidities, including recommendations 2 and 3 and the authors' scope and evidence limitations.
General information for musculoskeletal PRP, not individual clearance or a hepatitis treatment guide. Reviewed 31 October 2026. Your treating specialist's advice takes priority.